CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the use of high-dose vorinostat, an anti-cancer drug, combined with radiation therapy for treating recurrent high-grade gliomas. It aims to assess the drug's effectiveness in enhancing radiation-induced cell death and its impact on DNA repair mechanisms.
High-grade gliomas are the most frequent type of primary brain tumor in adults.
Despite optimal multi-modality treatment the disease almost always recurs, at which point median survival is less than a year.
Vorinostat (suberoylanilide hydroxamic acid) is the first member of a new class of anti-cancer compounds - histone deacetylase (HDAC) inhibitors, that modulate global gene expression.
The drug potentiates the anti-cancer activity of cytotoxic agents in a range of tumor types.
The standard dos…
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
